A Phase 2 interventional study of Placebo and Midomafetamine HCl in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Terminated at 1 site in Canada. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 30th largest by enrollment, is the only one that started in 2014, is one of 28 in phase 2, and was the 8th registered.
2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 21–70
Sunstone Medical · Sites in United States
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 18–75
Johns Hopkins University · Sites in United States
Ages 21+
Bronx VA Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 30 · Phase 3 6
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 69 across 2,202 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 25 across the 38 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 15 (88%) have results posted.
Among the 20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2014, is one of 13 in phase 2, and was the 8th registered.
Resilient Pharmaceuticals’s Stress Disorders, Post-Traumatic studies by the year they started, since 2004.
4 of the studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT07569159Sunstone MedicalMDMA Therapy in Veterans With PTSD | 2027-04-01 |
| NCT05837845Patricia SuppesMDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | 2027-05 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Resilient Pharmaceuticals’s 20 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare full dose MDMA-assisted therapy to placebo with therapy in participants with chronic, treatment-resistant PTSD. The main question it aims to answer is: Does MDMA-assisted therapy versus placebo with therapy reduce PTSD symptoms?
Participants will receive either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions spaced three to five weeks apart. During experimental sessions, participants receive an initial dose of 125 mg of MDMA HCl, or placebo, followed by a dose of 62.5 mg of MDMA HCl, or placebo. During this treatment period, participants will also undergo non-drug preparatory therapy sessions and non-drug integration sessions.
Researchers will compare PTSD symptoms in the MDMA-assisted therapy group to the placebo with therapy group to see if there is a reduction in symptoms after the treatment period. Safety measures will also be assessed between groups.
This randomized, double-blind, placebo-controlled clinical study will assess the safety and efficacy of MDMA-assisted therapy in treating chronic, treatment-resistant PTSD. In Stage 1, participants will be randomized to either MDMA-assisted therapy or placebo with therapy during two blinded experimental sessions, spaced three to five weeks apart. During experimental sessions, participants receive an initial dose of 125 mg of MDMA HCl, or placebo, followed by a dose of 62.5 mg of MDMA HCl, or placebo. During this treatment period, participants will also undergo non-drug preparatory therapy sessions and non-drug integration sessions. After this treatment period, participants will complete the primary endpoint assessment and the study will become unblinded.
Participants who were assigned to receive MDMA-assisted therapy will receive a third session of MDMA-assisted therapy that is open-label and participants assigned to receive placebo with therapy will have the option to enter Stage 2. Stage 2 will explore the optimal therapeutic dose of MDMA in a clinical titration dosing strategy. Participants will receive MDMA-assisted with an initial dose of 100 mg followed by a dose of 50 mg of MDMA HCl for the first experimental session. In the second and third experimental sessions, participants will have the option to increase the dose to an initial dose of 125 mg followed by a dose of 62.5 mg.
A blinded independent rater will assess PTSD symptoms via the CAPS-IV as well as other secondary outcome measures and safety measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo with therapy during each of two experimental sessions.
Drug: Placebo · Behavioral: Psychotherapy
Participants will receive MDMA (initial dose of 125 mg midomafetamine HCl followed by a supplemental dose of 62.5 mg midomafetamine HCl) with therapy during each of two experimental sessions.
Drug: Midomafetamine HCl · Behavioral: Psychotherapy
Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
Also known as: Inactive placebo
Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
Also known as: MDMA HCl, 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA
Psychotherapy before and after experimental sessions.
Change in Clinician-Administered PTSD Scale (CAPS-IV) Score From Baseline to Primary Endpoint
Clinician-administered and scored assessment of PTSD symptoms via structured interview, including global symptom severity, dichotomous diagnostic score and subscale scores. The Clinician-Administered PTSD Scale for DSM-4 (CAPS-4) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-4. It contains symptom subscales, a CAPS-4 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Change in PTSD Diagnostic Scale (PDS) Total Severity Score From Baseline to Primary Endpoint
The PTSD Diagnostic Scale (PDS) is a 49 item self-report measure designed to follow DSM-IV criteria for assessing PTSD. The PDS consists of a checklist to identify potentially traumatizing events experienced by the respondent and respondents then indicate which of the experienced events has troubled them the most in the last month and rate their response to this event at the time of its occurrence. Respondents then rate the severity of 17 items representing the cardinal symptoms of PTSD experienced in the past 30 days on a scale from 0 ("not at all") to 3 ("5 or more times a week") as well as the level of impairment caused by their symptoms across nine areas of life functioning. The 17 symptom severity items are summed to create a total symptom severity score, which ranges from 0 to 51, with higher scores indicating greater symptom severity and/or frequency.
Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Change in Beck Depression Inventory (BDI-II) Score From Baseline to Primary Endpoint
The BDI-II is a validated 21-item self-report measure of symptoms of depression according to DSM-IV criteria. A BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.
Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint
The GAF Scale is a numeric scale ranging from 0 (serious risk of causing harm to the self or others) through 100 (superior function) that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. The GAF is a reliable, validated measure of social functioning (Goldman, Skodol, and Lave, 1992). Higher scores indicate better functioning.
Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Change in Pittsburgh Sleep Quality Index (PSQI) Score From Baseline to Primary Endpoint
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 19 items that yield 7 component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Change in Dissociation Experiences Scale II (DES-II) Total Score From Baseline to Primary Endpoint
The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. It is an established measure of dissociative symptoms. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and averaging to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.
Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Change in Posttraumatic Growth Inventory (PTGI) Total Score From Baseline to Primary Endpoint
The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains 5 subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Responses to each question are made on a scale of 0 (no change) to 5 (great degree of change), with higher scores indicating greater personal growth. Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.
Time frame: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
Participants were recruited through printed ads, internet ads, referrals from other psychiatrists, psychotherapists or physicians, and through word of mouth.
| Milestone | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Started | 2 | 4 |
| Completed | 2 | 4 |
| Not completed | 0 | 0 |
| Milestone | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Started | 2 | 0 |
| Completed | 2 | 0 |
| Not completed | 0 | 0 |
Clinician-administered and scored assessment of PTSD symptoms via structured interview, including global symptom severity, dichotomous diagnostic score and subscale scores. The Clinician-Administered PTSD Scale for DSM-4 (CAPS-4) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-4. It contains symptom subscales, a CAPS-4 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Change in Clinician-Administered PTSD Scale (CAPS-IV) Score From Baseline to Primary Endpoint | -21.5 ± 12.02 | -17.3 ± 13.05 |
The PTSD Diagnostic Scale (PDS) is a 49 item self-report measure designed to follow DSM-IV criteria for assessing PTSD. The PDS consists of a checklist to identify potentially traumatizing events experienced by the respondent and respondents then indicate which of the experienced events has troubled them the most in the last month and rate their response to this event at the time of its occurrence. Respondents then rate the severity of 17 items representing the cardinal symptoms of PTSD experienced in the past 30 days on a scale from 0 ("not at all") to 3 ("5 or more times a week") as well as the level of impairment caused by their symptoms across nine areas of life functioning. The 17 symptom severity items are summed to create a total symptom severity score, which ranges from 0 to 51, with higher scores indicating greater symptom severity and/or frequency.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Change in PTSD Diagnostic Scale (PDS) Total Severity Score From Baseline to Primary Endpoint | -1.0 ± 5.66 | -5.3 ± 1.53 |
The BDI-II is a validated 21-item self-report measure of symptoms of depression according to DSM-IV criteria. A BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Change in Beck Depression Inventory (BDI-II) Score From Baseline to Primary Endpoint | -4.0 ± 2.83 | 2.0 ± 15.34 |
The GAF Scale is a numeric scale ranging from 0 (serious risk of causing harm to the self or others) through 100 (superior function) that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. The GAF is a reliable, validated measure of social functioning (Goldman, Skodol, and Lave, 1992). Higher scores indicate better functioning.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint | 5.0 ± 4.24 | 5.3 ± 3.86 |
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 19 items that yield 7 component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Change in Pittsburgh Sleep Quality Index (PSQI) Score From Baseline to Primary Endpoint | 1.0 ± 1.41 | -3.5 ± 3.32 |
The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. It is an established measure of dissociative symptoms. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from from "never" (0% of the time) to "always" (100%). The scale is scored by treating percentages as single digits and averaging to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Change in Dissociation Experiences Scale II (DES-II) Total Score From Baseline to Primary Endpoint | 8.4 ± 3.79 | -4.6 ± 13.63 |
The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains 5 subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Responses to each question are made on a scale of 0 (no change) to 5 (great degree of change), with higher scores indicating greater personal growth. Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.
| score on a scale | Placebo With Therapy | MDMA-assisted Therapy |
|---|---|---|
| Change in Posttraumatic Growth Inventory (PTGI) Total Score From Baseline to Primary Endpoint | 8.5 ± 14.85 | -3.7 ± 11.85 |
Collected over All AEs from baseline to the end of Stage 2 (approximately 10 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo With Therapy (Stage 1) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| MDMA-assisted Therapy (Stage 1) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Placebo With Therapy (Stage 2) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| SRRs: Placebo With Therapy | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| SRRs: MDMA-assisted Therapy | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Placebo With Therapy (Stage 1) | MDMA-assisted Therapy (Stage 1) | Placebo With Therapy (Stage 2) | SRRs: Placebo With Therapy | SRRs: MDMA-assisted Therapy |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/2 | 1/4 | 0/2 | 2/2 | 4/4 |
| HeadacheNervous system disorders | 0/2 | 1/4 | 0/2 | 2/2 | 4/4 |
| AnxietyPsychiatric disorders | 0/2 | 2/4 | 0/2 | 2/2 | 4/4 |
| InsomniaPsychiatric disorders | 0/2 | 1/4 | 0/2 | 2/2 | 4/4 |
| Difficulty ConcentratingGeneral disorders | 0/2 | 0/4 | 0/2 | 2/2 | 3/4 |
| Low moodGeneral disorders | 0/2 | 0/4 | 0/2 | 2/2 | 3/4 |
| Muscle TensionGeneral disorders | 0/2 | 0/4 | 0/2 | 2/2 | 3/4 |
| Need More SleepGeneral disorders | 0/2 | 0/4 | 0/2 | 2/2 | 3/4 |
| NauseaGastrointestinal disorders | 0/2 | 1/4 | 0/2 | 1/2 | 3/4 |
| RuminationsGeneral disorders | 0/2 | 0/4 | 0/2 | 1/2 | 3/4 |
| Age, Continuous(years) | Placebo With Therapy | MDMA-assisted Therapy | Total |
|---|---|---|---|
| Mean | 44.0 ± 12.66 | 49.6 ± 7.9 | 47.7 ± 8.82 |
| Sex: Female, Male(Participants) | Placebo With Therapy | MDMA-assisted Therapy | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 1 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Placebo With Therapy | MDMA-assisted Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 4 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo With Therapy | MDMA-assisted Therapy | Total |
|---|---|---|---|
| Race — White | 2 | 3 | 5 |
| Race — Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2014 to primary completion in Sep 2015, 10 months.
Results were first posted in Aug 2021, 5 years 10 months after primary completion. A results delay was requested in Dec 2017.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Stress Disorders, Post-Traumatic →